In spite of its extensive medico economic impact, proteinuria remains a poorly understood symptom of the kidneyglomerular filtration barrier dysfunction. At the same time the incidence of end-stage renal disease is increasing in all European counties with only expensive and untargeted treatments available. Here we will use the most up-to-date findings and techniques of molecular biology combined with the extensively shown expertise at the area proposed, to bridge the findings of basic molecular research to direct patient treatment. The goal is to develop markers suitable for early diagnostics, prevention, progression and prognosis for patients with protenuric diseases. The functional genomics of a key molecule for proteinuria, nephrin, as recently identified, will thus be thoroughly studied and the same potential of the emerging binding proteins evaluated. Devices for early diagnostics and patient segmentation wilI be worked out, devices for cDNA array chips for complete kidney glomerular gene expression developed, the intellectual property rights appropriately protected and connections to diagnostics industry developed.
All the main objectives of the project were achieved to a great extent. During the project the original technical annex was modified in the middle of the project. The main reasons for this were that some techniques described in the original technical annex were no longer relevant. In addition, due to some new results obtained in the progress of the project, some research subjects were extended in the project. However, the total workload and focus remained grossly the same although some experimental approaches were left out.
Funding SchemeCSC - Cost-sharing contracts
2300 RA Leiden
60590 Frankfurt Am-main